INOCARDIA
Inocardia is a Coventry University spinout focused on the provision of Contract Research Services via the development of assays targeted at the biotech and pharmaceutical sectors. Inocardia has developed the ‘work-loop’ model as a pre-clinical myocardial assay assessing cardiac contractility in normal, diseased and ageing myocardium in order to determine the cardiovascular safety of lead pharmaceutical compounds. The Coventry University work-loop assay is the only relevant in-vitro human model of cardio-toxicity available worldwide. Both the pharmaceutical industry and regulators recognise that contractility assessment is currently fraught with problems.
INOCARDIA
Industry:
Biopharma Biotechnology Life Science
Founded:
2013-01-01
Address:
Coventry, Coventry, United Kingdom
Country:
United Kingdom
Website Url:
http://www.inocardia.co.uk
Total Employee:
1+
Status:
Active
Contact:
+44 (0)7988 563489
Total Funding:
229 K GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Content Delivery Network Nginx Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS
Similar Organizations
LNC Therapeutics
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases.
Tierra Biosciences
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Current Employees Featured
Founder
Investors List
Mercia Fund Managers
Mercia Fund Managers investment in Venture Round - InoCardia
Official Site Inspections
http://www.inocardia.co.uk
- Host name: www.flcomaha.org
- IP address: 69.163.136.50
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "InoCardia"
InoCardia - Cardiac Contractility
InoCardia brings superior, predictive, Award-Winning cardio-toxicity assays to pharmaceutical R&D. ... UK. In 2019 we moved into our new, purpose built CardioTox lab within the Alison …See details»
InoCardia - Crunchbase Company Profile & Funding
Inocardia is a Coventry University spinout focused on the provision of Contract Research Services via the development of assays targeted at the biotech and pharmaceutical sectors. Inocardia …See details»
InoCardia Company Profile 2024: Valuation, Funding & Investors
Co-Founder & Chief Scientific Officer: To view InoCardia’s complete executive team members history, request access » InoCardia Signals. Growth Rate. 0.80% Weekly ... Who are …See details»
INOCARDIA LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for INOCARDIA LIMITED of COVENTRY. Get the latest business insights from Dun & Bradstreet.See details»
INOCARDIA LIMITED - LinkedIn
INOCARDIA LIMITED | 216 followers on LinkedIn. InoCardia offers predictive Award-Winning cardiac screening assays & virtual tools for pharma & biotech industry. | We are a UK-based, …See details»
InoCardia - Overview, News & Similar companies | ZoomInfo.com
Who is InoCardia. InoCardia is an organisation dedicated to bringing superior, predictive cardiac contractility to early drug discovery. By manipulating pre- and aft er-load, and by directly …See details»
Inocardia - VentureRadar
Epistem United Kingdom Publicly Traded Epistem Limited is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Founded on ground …See details»
InoCardia - Products, Competitors, Financials, Employees, …
InoCardia specializes in predictive cardiotoxicity assessment services within the pharmaceutical and biotechnology domains. Use the CB Insights Platform to explore InoCardia's full profile. …See details»
InoCardia Company Profile - Office Locations, Competitors ... - Craft
InoCardia has 1 employees at their 1 location and $391.23 k in total funding,. See insights on InoCardia including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
InoCardia: Delivering Improved Cardiac Safety Liabilities for ...
Research underpinning InoCardia’s work received a recent ‘Technological Innovation Award’ from the global Safety Pharmacology Society in 2020, and in December 2020 Maddock was …See details»
InoCardia: Novel human-cell based assay for assessment of ...
May 1, 2016 To research organisations: Reduced toxicology screening costs; Reduced attrition rates; Reduced numbers of animals used; ... This Innovate UK/NC3R grant will support …See details»
Mercia makes £229,000 investment in Inocardia - Mercia
Drug screening services spinout secures investment package Henley-in-Arden, 21 July 2014. Technology investor Mercia Fund Management has announced a £229,000 investment in …See details»
InoCardia: Contractome-AI - Coventry University
Following funding from an EIT-Digital-Horizon 2020 award InoCardia has launched an online virtual screen named ‘The Contractome-AI’. Rather than physical testing in the lab, this …See details»
Clinical Trials on tissues of human heart now possible in UK
A UK based new start-up is developing a unique method for testing out the impact of drugs on the cardio-vascular system without resorting to animal testing or through clinical trials of an early …See details»
Mercia Fund Management makes £229,000 investment in InoCardia
Drug screening services spinout secures investment package Henley-in-Arden, 21 July 2014. Technology investor Mercia Fund Management has announced a £229,000 investment in …See details»
Drug-Testing Technology Saves Millions of Pounds and Lives
May 12, 2022 In 2020, the business was expanded to include InoCardia’s cardiac safety assessment portfolio and was supported by over £2.5m funding from InnovateUK, NC3R, …See details»
Jeremy Billson - CEO - InoCardia - LinkedIn
CEO at InoCardia · Experience: InoCardia · Location: Greater Cambridge Area · 336 connections on LinkedIn. View Jeremy Billson’s profile on LinkedIn, a professional community of 1 billion …See details»
Bespoke In Silico Inotropy Prediction - cresset-group.com
* Cresset, Cambridgeshire, UK [email protected] cresset-group.com ** InoCardia, Coventry, UK [email protected] inocardia.co.uk Introduction Inotropy –the ability …See details»
Two Safety Pharmacology Society awards for Coventry University
Researchers from the Centre for Sport, Exercise and Life Sciences (CSELS) and Coventry University spin-out company InoCardia have been presented with two prestigious awards from …See details»
Coventry University spin-out receives £50,000 to test COVID-19 …
Jun 11, 2020 InoCardia has been awarded £50,000 by the UK government to reduce the risk of new COVID-19 drugs causing life threatening effects on the heart. This is vital because of the …See details»